Last reviewed · How we verify
emodepside (BAY 44-4400)
Emodepside is a benzimidazole anthelmintic that acts as a glutamate-gated chloride channel agonist.
Emodepside is a benzimidazole anthelmintic that acts as a glutamate-gated chloride channel agonist. Used for Treatment of cutaneous and visceral larva migrans, strongyloidiasis, and other nematode infections.
At a glance
| Generic name | emodepside (BAY 44-4400) |
|---|---|
| Also known as | Profender® (in combination with praziquantel) FOR VETERINARY USE, Procox® (in combination with toltrazuril) FOR VETERINARY USE |
| Sponsor | Swiss Tropical & Public Health Institute |
| Drug class | benzimidazole anthelmintic |
| Target | glutamate-gated chloride channel |
| Modality | Small molecule |
| Therapeutic area | Parasitology |
| Phase | Phase 3 |
Mechanism of action
This mechanism of action results in an increase in chloride ion permeability in the nematode muscle and pharyngeal muscle, leading to paralysis and death of the parasite.
Approved indications
- Treatment of cutaneous and visceral larva migrans, strongyloidiasis, and other nematode infections
Common side effects
- Gastrointestinal disturbances
Key clinical trials
- Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections (PHASE3)
- Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections (PHASE3)
- A Study to Learn About How Much Emodepside Gets Absorbed in the Blood and How Food Affects Its Absorption When Given as a New Type of Tablet to Healthy Participants (PHASE1)
- Emodepside Phase II Trial for Treatment of Onchocerciasis (PHASE2)
- Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside (PHASE1)
- First in Man Clinical Trial of Emodepside (BAY 44-4400) (PHASE1)
- Relative Bioavailability Study of Emodepside IR-tablets and Solution (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |